Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Pioglitazone and vitamin E
12 evidence topics · 8 sources
AASLD practice guidance statements: pioglitazone and vitamin E
“Pioglitazone improves NASH and can be considered for patients with NASH in the context of patients with T2DM” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vitamin E can be considered in select individuals as it improves NASH in some patients without diabetes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Available data on semaglutide, pioglitazone, and vitamin E do not demonstrate an antifibrotic benefit, and these compounds have not been carefully studied in patients with cirrhosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASLD update to the practice guidance on resmetirom: regulatory status of pioglitazone and vitamin E for MASH
EASL-EASD-EASO guideline recommendations: pioglitazone and vitamin E not recommended as MASH-targeted therapies
ADA Standards of Care recommendations 4.27a, 4.27b, and 4.30a: pioglitazone in adults with type 2 diabetes and MASH
“In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combination therapy with pioglitazone plus GLP-1 RA can be considered for the treatment of hyperglycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) because of potential beneficial effects on MASH. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH. B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the context of treating hyperglycemia in individuals with type 2 diabetes with MASLD, where the low cost of pioglitazone and any liver improvement would be an added benefit to glycemic management, these plans would be potentially cost-effective for the treatment of MASLD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ADA Standards of Care: vitamin E with and without type 2 diabetes
“Vitamin E may be beneficial for the treatment of MASH in individuals without diabetes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, in individuals with type 2 diabetes, vitamin E monotherapy was found to be ineffective in a small RCT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PIVENS: pioglitazone 30 mg or vitamin E 800 IU vs placebo in 247 adults without diabetes, 96 weeks, intention-to-treat primary analysis
“We randomly assigned 247 adults with nonalcoholic steatohepatitis and without diabetes to receive pioglitazone at a dose of 30 mg daily (80 subjects), vitamin E at a dose of 800 IU daily (84 subjects), or placebo (83 subjects), for 96 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis was an intention-to-treat analysis in which the proportions of subjects in each active-treatment group (pioglitazone and vitamin E) in whom there was improvement in nonalcoholic steatohepatitis were compared with the proportion of subjects in the placebo group in whom there was improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vitamin E therapy, as compared with placebo, was associated with a significantly higher rate of improvement in nonalcoholic steatohepatitis (43% vs. 19%, P = 0.001), but the difference in the rate of improvement with pioglitazone as compared with placebo was not significant (34% and 19%, respectively; P = 0.04).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“both agents were associated with reductions in hepatic steatosis (P = 0.005 for vitamin E and P<0.001 for pioglitazone) and lobular inflammation (P = 0.02 for vitamin E and P = 0.004 for pioglitazone) but not with improvement in fibrosis scores (P = 0.24 for vitamin E and P = 0.12 for pioglitazone).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PIVENS: resolution of steatohepatitis with pioglitazone, as summarized in the AASLD practice guidance
“In the PIVENS trial, pioglitazone treatment did not meet the a priori primary endpoint of a ≥2-point reduction NAS without worsening of fibrosis, although 47% had NASH resolution compared with 21% of participants receiving placebo (p <0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pioglitazone 45 mg/d for 18 months in 101 randomized participants with NASH and prediabetes or type 2 diabetes
“Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single-center study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pioglitazone safety: weight gain, heart failure, fractures, and bladder cancer in guideline texts
“Potential side effects associated with pioglitazone include weight gain, osteoporosis in postmenopausal women, a debated risk of bladder cancer, and potential risk for worsening heart failure in those with preexisting cardiac dysfunction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“its use in clinical practice has been overtaken by the increasing use of newer antidiabetic agents such as glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium glucose cotransporter-2 (SGLT-2) inhibitors (SGLT-2i) with pleiotropic metabolic benefits, most notably weight loss and reduction in cardiovascular mortality” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pioglitazone causes dose-dependent weight gain (15 mg/day, mean weight gain of 1–2%; 45 mg/day, mean weight gain of 3–5%), which can be blunted or reversed if combined with SGLT2 inhibitors or GLP-1 RAs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pioglitazone increases fracture risk, may promote heart failure if used in individuals with preexisting congestive heart failure, and may increase the risk of bladder cancer, although this remains controversial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pioglitazone safety: boxed warning for congestive heart failure in the FDA label
Pioglitazone safety in PIVENS: weight gain at week 96 and cardiovascular events
“There was a significant improvement in insulin resistance only in the pioglitazone group, but that group was also the only group that had a significant mean weight gain (a mean increase of 4.7 kg at week 96, P<0.001 for the comparison with placebo)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A similar number of cardiovascular events occurred among subjects taking placebo (12 events), those taking vitamin E (12), and those taking pioglitazone (10). No cases of congestive heart failure were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vitamin E safety and advanced fibrosis outcomes in the AASLD practice guidance
“Although no study has demonstrated that vitamin E meaningfully reduces fibrosis, a retrospective study of 236 patients with NASH and advanced fibrosis showed that vitamin E use was associated with lower rates of hepatic decompensation (37% vs. 62%, p = 0.04) and higher transplant free survival (78% vs. 49%, p < 0.01)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Concern about the risks of vitamin E on bleeding and specifically hemorrhagic stroke has been raised, but prospective data are needed to confirm this observation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, data demonstrating a relationship between vitamin E and prostate cancer are conflicting” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Such potential risks should be discussed with patients before initiation of long-term high-dose (eg, 800 IU daily) vitamin E therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote